# US 2024/0199581 A1 · Therapeutics for the degradation of mutant braf

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199581 A1
- Document ID: US20240199581A1
- Status: Published application
- Kind: A1
- Application number: 18/534,395
- Filed: 2023-12-08
- Published: 2024-06-20
- Earliest claimed: 2021-06-08
- Assignees: C4 Therapeutics, Inc.
- Applicants: C4 Therapeutics, Inc.
- Inventors: Christopher G. Nasveshuk; Katrina L. Jackson; Yanke Liang; Robert T. Yu; Martin Duplessis; Mark E. Fitzgerald; Victoria Garza; Andrew Charles Good; Morgan Welzel O'Shea; Gesine Kerstin Veits; Cosimo Dolente; David Stephen Hewings; Daniel Hunziker; Daniela Krummenacher; Piergiorgio Franceso Tommaso Pettazzoni; Juergen Wichmann
- Web page: https://patentgrep.com/patent/US20240199581A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 405/14: containing three or more hetero rings
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 495/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

## Claims

### Claim 1

A compound of Formula I, Formula II, Formula III, Formula IV, Formula V, or Formula VI:
or a pharmaceutically acceptable salt thereof;
wherein
A1 is selected from —NR2— and —CHR2—;
R1 is selected from hydrogen, alkyl and cycloalkyl;
R2 is selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
or R1 and R2 together with the nitrogen atom to which they are attached form heterocycloalkyl optionally substituted with one or two R3;
R2′ is selected from hydrogen, alkyl, cycloalkyl and haloalkyl;
or R1 and R2′ together with the carbon atom to which they are attached form cycloalkyl optionally substituted with one or two R3;
each R3 is independently selected from hydrogen, halogen, alkyl, cycloalkyl and alkoxy;
R4 is selected from hydrogen, alkyl, cyano and halogen;
R5 is selected from hydrogen, alkyl, cyano and halogen;
A2 is selected from —O—, —NH— and —(C═O)—;
A22 is selected from —O—, and —NH—;
A24 is selected from a bond, —CH2—, —NH— and —O—;
W1 is selected from —N— and —CH—;
W2 is selected from —N—, and —CR26—;
R6 is selected from hydrogen, halogen, hydroxy, amino, dialkyl]amino, alkoxy, alkyl and alkoxyalkyl;
R26 is selected from hydrogen, halogen, hydroxy, amino, alkoxy and alkyl;
A3 is selected from a bond, —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH(CH3)—CH2—CH2—, —CH2—CH(CH3)—CH2—, —CH2—CH2—CH(CH3)—, —CH2—CH2—CH2—CH2— and —CH2—CH2—CH2—CH2—CH2—;
A23 is selected from a bond, —O— and —CH2—:
A is selected from a bond, pyrimidinyl, pyridinyl, pyrazolyl and 3-azabicyclo[3.1.0]hexyl;
A30 is selected from a bond, —CH2—, pyrimidinyl, pyridinyl, pyrazolyl and 3-azabicyclo[3.1.0]hexyl;
B is selected from phenyl, piperidinyl, piperazinyl, 1,4-diazacycloheptyl, 1-oxa-8-azaspiro[4.5]decyl, 1-oxa-9-azaspiro[5.5]undecyl, 2,8-diazaspiro[4.5]decyl, 2-azaspiro[4.5]decyl, 3-azabicyclo[3.1.0]hexyl, 3-azaspiro[5.5]undecyl, 7-azaspiro[3.5]nonyl, 1,1-dioxo-1Iambda6-thia-8-azaspiro[4.5]decyl, 1-oxaspiro[4.5]decyl, 1-methyl-1,8-diazaspiro[4.5]decyl, 1,8-diazaspiro[4.5]decyl, and 8-azaspiro[4.5]decyl; wherein B is optionally substituted with one or two substituents independently selected from halogen, alkyl and alkoxy;
B2 is selected from phenyl, piperidinyl, piperazinyl, 1,4-diazacycloheptyl, 1-oxa-8-azaspiro[4.5]decyl, 1-oxa-9-azaspiro[5.5]undecyl, 2,8-diazaspiro[4.5]decyl, 2-azaspiro[4.5]decyl, 3-azabicyclo[3.1.0]hexyl, 3-azaspiro[5.5]undecyl, 7-azaspiro[3.5]nonyl and 8-azaspiro[4.5]decyl; wherein B2 is optionally substituted with one or two substituents independently selected from halogen, alkyl and alkoxy;
B3 is selected from phenyl, piperidinyl, piperazinyl, 1,4-diazacycloheptyl, 1-oxa-8-azaspiro[4.5]decyl, 1-oxa-9-azaspiro[5.5]undecyl, 2,8-diazaspiro[4.5]decyl, 2-azaspiro[4.5]decyl, 3-azabicyclo[3.1.0]hexyl, 3-azaspiro[5.5]undecyl, 7-azaspiro[3.5]nonyl, 1,1-dioxo-1Iambda6-thia-8-azaspiro[4.5]decyl, 1-oxaspiro[4.5]decyl, 1-methyl-1,8-diazaspiro[4.5]decyl, 1,8-diazaspiro[4.5]decyl and 8-azaspiro[4.5]decyl;
n is 0 or 1;
A4 is selected from a bond, —CH2—, —(SO2)—CH2—, —CH(CH2OH)—, —NH— and —O—:
A14 is selected from a bond, —CH2—, —CH2—CH2—, —CH(CH2OH)—, —NH—, —O—, cycloalkyl and alkyl]amino;
C is selected from azepanyl, azetidinyl, cycloalkyl, piperazinyl and piperidinyl; wherein C is optionally substituted with one or two substituents independently selected from, hydroxy, alkyl and alkoxy;
D is selected from
R7 is selected from hydrogen, alkyl, cyano, halogen, and alkoxy;
R8 is selected from hydrogen, alkyl, cyano, halogen, and alkoxy;
R9 is selected from hydrogen, alkyl, cyano, halogen, and alkoxy;
R17 is selected from hydrogen, alkyl, cyano, hydroxy, cycloalkyl, halogen and alkoxy;
R18 is selected from hydrogen, alkyl, cyano, hydroxy, cycloalkyl, halogen and alkoxy;
R19 is selected from hydrogen, alkyl, cyano, hydroxy, cycloalkyl, halogen and alkoxy;
A5 is —CH— or —N—;
A15 is selected from a bond, —O— and —NH—;
A6 is —CH— or —N—;
Linker is a bivalent chemical group selected from
wherein:
X1 and X2 are independently at each occurrence selected from bond, heterocycle, NR2, C(R2)2, O, C(O), and S;
R20, R21, R22, R23, and R24 are independently at each occurrence selected from the group consisting of bivalent moieties selected from bond alkyl, —C(O)—, —C(O)O—, —OC(O)—, —SO2—, —S(O)—, —C(S)—, —C(O)NR 2-, —NR 2C(O)—, —O—, —S—, —NR2—, —C(R40R40)—, —P(0)(OR36)O -, —P(O)(OR36)—, bicycle, alkene, alkyne, haloalkyl, alkoxy, aryl, heterocycle, heteroaryl, lactic acid, glycolic acid, and carbocycle; each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R;
R36 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, arylalkyl, heteroarylalkyl, alkene, alkyne, aryl, heteroaryl, and heterocycle; and
R40 is independently at each occurrence selected from the group consisting of hydrogen, alkyl, alkene, alkyne, fluoro, bromo, chloro, hydroxyl, alkoxy, azide, amino, cyano, —NH(alkyl), —N(alkyl)2, —NHSO2(alkyl), —N(alkyl)SO2alkyl, —NHSO2(aryl, heteroaryl or heterocycle), —N(alkyl)SO2(aryl, heteroaryl or heterocycle), -NHSO2alkenyl, —N(alkyl)SO2alkenyl, —NHSO2alkynyl, —N(alkyl)SO2alkynyl, haloalkyl, aryl, heteroaryl, heterocycle, and cycloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is of Formula:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein A5 is —N—.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R7 is methyl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R8 and R6 are both hydrogen.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R9 is R5 are both fluorine.

### Claim 7 (depends on 1)

The compound of claim 1, wherein B is
and C is

### Claim 8 (depends on 1)

The compound of claim 1, wherein A2 is —O—.

### Claim 9 (depends on 1)

The compound of claim 1, wherein A3 is bond.

### Claim 10 (depends on 1)

The compound of claim 1, wherein n is 1.

### Claim 11 (depends on 1)

The compound of claim 1, wherein A1 is —NCH3—.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R1 is ethyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R4 is cyano.

### Claim 14 (depends on 2)

The compound of claim 2, wherein the compound is of formula (I-A):
or pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 2)

The compound of claim 2, wherein the compound is of formula:
or pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 2)

The compound of claim 2, wherein the compound is of formula:
or pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 2)

The compound of claim 2, wherein the compound is of formula:
or pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 2)

The compound of claim 2, wherein the compound is of formula:
or pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 2)

The compound of claim 2 selected from the group consisting of.
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 2)

The compound of claim 2 selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 2)

The compound of claim 2 selected from the group consisting of
or a pharmaceutically acceptable salt thereof .

### Claim 22 (depends on 2)

The compound of claim 2 selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The compound of claim 22, wherein the compound is of structure
or a pharmaceutically acceptable salt thereof .

### Claim 24 (depends on 22)

The compound of claim 22, wherein the compound is of structure
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 22)

The compound of claim 22, wherein the compound is of structure
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 1)

A method of treating a mutant BRAF mediated cancer comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to a human patient in need thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the mutant BRAF mediated cancer is selected from the group consisting of melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, Erdheim-Chester disease, Langerhans histiocytosis, ganglioglioma, glioma, glioblastoma, hairy cell leukemia, multiple myeloma, lung cancer, ovarian cancer, pilomyxoid astrocytoma, anaplastic pleomorphic xanthoastrocytoma, astrocytoma, papillary thyroid cancer, anaplastic thyroid cancer, pancreatic cancer, thoracic clear ceII sarcoma, salivary gland cancer, and microsatellite stable colorectal cancer.

### Claim 28 (depends on 26)

The method of claim 26, wherein the compound is of formula:
or a pharmaceutically acceptable salt thereof.

### Claim 29 (depends on 27)

The method of claim 27, wherein the compound is of formula:
or a pharmaceutically acceptable salt thereof.
